# Amnova heart-repair hydrogel: source note
Reviewed 2026-10-13 for Managing Expectations Health.

## Scope and result
Real company and research program; reported preclinical animal findings; no established human efficacy or clinical availability in reviewed sources. This source review is not medical advice.

## Supplied social lead
https://www.facebook.com/share/p/1Dez18bEkH/?mibextid=wwXIfr
The accessible Cheryl Rae post describes Pilar Ferrer, age 25, an amniotic-membrane-inspired injectable gel, claimed vascularization/inflammation/repair effects and animal testing. It explicitly says preclinical and not yet in human trials. Caption recovered through web extraction. Attached image not independently inspected; no video was supplied. Unrelated reader comments are excluded from this public package.

## Evidence and access
- https://www.amnova-biotech.com/ — current live company homepage fetched directly, HTTP 200. Team and development roadmap confirmed. Exact clinical disclaimer: “Amnova's therapy is under development and is not yet available for clinical use.” Company source; not independent efficacy evidence.
- https://www.lanacion.com.ar/tecnologia/una-startup-argentina-creo-un-inedito-hidrogel-capaz-de-reparar-el-corazon-tras-un-infarto-nid20082026/ — August 20, 2026 interview, recovered directly as UTF-8. Reports age 25, named team, sheep work and estimated two years to clinical studies. Timing is a forecast, not approval.
- https://www.amnova-biotech.com/post/amnova-biotech-is-making-progress-with-an-injectable-hydrogel-for-cardiac-regeneration-following-a-h — extracted company-hosted Mercado coverage dated April 10, 2026, reposted April 24. Text reports 28-day animal improvements and recombinant regenerative factors. Direct follow-up returned HTTP 404; do not treat the old page as currently live. Current homepage independently confirms ongoing development.
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6986802/ — Henry et al., Development of Injectable Amniotic Membrane Matrix for Post-Myocardial Infarction Tissue Repair. DOI https://doi.org/10.1002/adhm.201900544. Full text read. Related rat research showing improved contractility and reduced fibrosis; separate team/material, not Amnova product validation or a human study.
- https://www.heart.org/en/health-topics/heart-attack/treatment-of-a-heart-attack — authoritative patient-care context; medication and procedures remain important.

## Limits
No full peer-reviewed Amnova sheep report or human outcome report located in this review. Sample size, controls, effect sizes, adverse events and long-term follow-up were not independently verified. Absence of a located paper is not proof that no paper exists. Public composition descriptions differ; exact formulation is not established. No clinical-trial registration or authorization claimed. Do not infer older-scar reversal, survival gains or availability from a 28-day animal result.

## Assets
Original editorial SVG, not a clinical illustration or depiction of experimental results. Article includes annotated source links. Raw third-party pages are retained only in local working files; unrelated social comments are not republished.